You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Lung cancer

EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules

  • Diagnostics guidance
  • Reference number: DG46
  • Published:  23 February 2022

Register as a stakeholder

  • Guidance
  • Tools and resources
  • Information for the public
  • History

Research recommendations coming out of this guidance

  • Further research is recommended on:

    • The accuracy of EarlyCDT Lung, and the validity of the risk models used to combine EarlyCDT Lung results with the Brock and the Herder risk models.
    • The impact of EarlyCDT Lung on clinical management decisions.

    A large retrospective audit is recommended to:

    • Understand how patient and nodule characteristics impact on malignancy prevalence and disease progression.
    • Understand current practice regarding clinical management of people with intermediate-risk lung nodules.
    • Determine the clinical consequences of CT surveillance, including the likelihood of disease progression during CT surveillance.
    • Determine the likelihood and impact of unnecessary biopsy or resection of indolent and benign nodules
    • If existing data on these points is limited or not routinely collected, a prospective data collection should be undertaken to obtain it.

Back to top